SS-20
No single human route established in this referenceAnimal / laboratory reference
Research reference
Animal / laboratory study
SS-20 mitochondrial experiments
Experimental exposures only
Neurotoxicity and mitochondrial assays
SS-20/SS-31 primary study (2009) ↗When results may show
SS-20
Evidence gap- When change was measured
- Dopamine-cell and mitochondrial findings do not establish a human Parkinson, energy or longevity timeline.
- When to assess
- Neurotoxicity and mitochondrial assays
- Conditions and limitations
- MPTP-exposed mice, cultured cells and isolated mitochondria. No human starting amount, course length, cycling, mixing volume or time-to-result is established by this experiment. SS-31/elamipretide findings cannot be substituted for SS-20.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: SS-20/SS-31 primary study (2009)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 10hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- SS-20/SS-31 primary study (2009)No human starting amount, course length, cycling, mixing volume or time-to-result is established by this experiment. SS-31/elamipretide findings cannot be substituted for SS-20.